To determine whether anti-PD-1 therapy in combination with a TLR9 agonist enhances antitumor activity in an HCC mouse model, Subcutaneous and orthotopic Hepa1-6 tumor model was used for single-drug and combined-drug treatment. The gene discussed is TLR9; the disease is neoplasm.